Coumarin glycosides and their α-glucosidase inhibitory effects from Impatiens eberhardtii

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-02-08 DOI:10.1016/j.phytol.2025.01.998

Nguyen Thi Thuy Linh , Nguyen Thi Cuc , Trinh Thi Thuy , Tran Duc Quan , Ba Thi Cham , Do Thi Thao , Nguyen Chi Bao , Vu Tien Chinh , Phan Van Kiem , Nguyen Xuan Nhiem , Dang Viet Hung , Nguyen Thi Hoang Anh

{"title":"Coumarin glycosides and their α-glucosidase inhibitory effects from Impatiens eberhardtii","authors":"Nguyen Thi Thuy Linh , Nguyen Thi Cuc , Trinh Thi Thuy , Tran Duc Quan , Ba Thi Cham , Do Thi Thao , Nguyen Chi Bao , Vu Tien Chinh , Phan Van Kiem , Nguyen Xuan Nhiem , Dang Viet Hung , Nguyen Thi Hoang Anh","doi":"10.1016/j.phytol.2025.01.998","DOIUrl":null,"url":null,"abstract":"<div><div>Two new coumarin glycosides, namely emberharins A and B (1 and 2), and eight known compounds, fraxidin (3), kaempferol (4), kaempferol 3-O-β-glucopyranoside (5), kaempferol 3-O-α-L-rhamopyranoside (6), quercetin (7), isoquercitrin (8), indole-3-cacboxylic methyl ester (9), and lariciresinol 9-O-β-D-glucopyranoside (10) were isolated from the methanol extract of Impatiens eberhardtii Tardieu aerial parts. Their chemical structures were elucidated by 1D- and 2D-nuclear magnetic resonance spectroscopy, mass spectroscopy, and then evaluated in comparison with literature data. Compounds 5, 6, and 7 showed significant inhibitory α-glucosidase with IC50 values of 181.6 ± 6.7, 170.6 ± 15.2, and 157.7 ± 5.9 μg/mL, respectively. These findings suggest that the isolated compounds, particularly 5, 6, and 7 hold potential as α-glucosidase inhibitors, which warrants further investigation for their antidiabetic properties.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"66 ","pages":"Pages 15-18"},"PeriodicalIF":1.3000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390025010055","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Two new coumarin glycosides, namely emberharins A and B (1 and 2), and eight known compounds, fraxidin (3), kaempferol (4), kaempferol 3-O-β-glucopyranoside (5), kaempferol 3-O-α-L-rhamopyranoside (6), quercetin (7), isoquercitrin (8), indole-3-cacboxylic methyl ester (9), and lariciresinol 9-O-β-D-glucopyranoside (10) were isolated from the methanol extract of Impatiens eberhardtii Tardieu aerial parts. Their chemical structures were elucidated by 1D- and 2D-nuclear magnetic resonance spectroscopy, mass spectroscopy, and then evaluated in comparison with literature data. Compounds 5, 6, and 7 showed significant inhibitory α-glucosidase with IC₅₀ values of 181.6 ± 6.7, 170.6 ± 15.2, and 157.7 ± 5.9 μg/mL, respectively. These findings suggest that the isolated compounds, particularly 5, 6, and 7 hold potential as α-glucosidase inhibitors, which warrants further investigation for their antidiabetic properties.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.